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a b s t r a c t
Attention Deﬁcit/Hyperactivity Disorder (ADHD) and autism spectrum disorder (ASD) are highly
comorbid, and both disorders share executive function deﬁcits. Accumulating evidence suggests that
ASD patients have signiﬁcantly lower peripheral oxytocin (OXT) levels compared with their normal
counterparts, and that the repetitive behavior seen in ASD is related to abnormalities in the OXT system.
In this study, we investigated whether serum levels of OXT are altered in pediatric patients with ADHD.
We measured serum OXT levels: drug naive ADHD (n¼23), medicated ADHD (n¼13), and age- and
sex- matched, neurotypical controls (n¼22). Patients were evaluated using the ADHD-RS. Serum levels
of OXT in total subjects with ADHD were signiﬁcantly decreased compared with those of neurotypical
controls, and serum levels of OXT in drug naive ADHD patients were signiﬁcantly lower than those in
medicated ADHD patients. Interestingly, there was a signiﬁcant negative correlation between serum OXT
levels and ADHD-RS total scores, as well as ADHD-RS inattentive scores in all ADHD patients. In
conclusion, this study suggests that decreased levels of OXT may play a role in the pathophysiology of
patients with ADHD and its inherent inattentiveness.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Attention Deﬁcit/Hyperactivity Disorder (ADHD) is a common
chronic psychiatric disorder, characterized by a pattern of devel-
opmentally inappropriate inattention, motor restlessness and
impulsivity, which affects between 3 and 7% of school age children,
according to DSM-IV criteria (American Psychiatric Association,
1994; Polanczyk et al., 2007). Prospective follow-up studies found
that approximately 50% of children with ADHD show symptoms
that continue into adulthood, and when left untreated, are asso-
ciated with substance abuse, depression, unemployment and crim-
inal offenses (Biederman et al., 2006; Molina et al., 2009). However,
the precise neurobiological mechanisms underlying the pathophy-
siology of ADHD are currently unknown. One way to combat this
disorder would be to discover novel biomarkers. Biomarkers would
aid both diagnosis and the development of effective psychiatric
treatment (Scassellati et al., 2012; Thome et al., 2012).
Autism spectrum disorder (ASD) is deﬁned by impairment in
communication and social interaction, as well as by restricted and
repetitive behavior, according to DSM-IV criteria (American
Psychiatric Association, 1994). Accumulating evidence suggests that
ASD patients have signiﬁcantly lower peripheral oxytocin (OXT)
levels relative to healthy counterparts, and that the repetitive
behavior in ASD is related to abnormalities in the OXT system, abn-
ormalities which can be partially ameliorated by synthetic oxytocin
infusion (Modahl et al., 1998; Hollander et al., 2003, 2007).
ADHD and ASD are highly comorbid and both disorders share
executive function deﬁcits (Willcutt et al., 2005, Corbett et al., 2009;
Rommelse et al., 2011), including poor cognitive ﬂexibility (Hill,
2004; Willcutt et al., 2005; Sanders et al., 2008), which has been
linked to repetitive behavior in ASD (Yerys et al., 2009). The clinical
importance of this behavioral and cognitive overlap has been high-
lighted by changes to the DSM-5, which now allows co-diagnosis of
ADHD and ASD (American Psychiatric Association, 2013).
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It is reported that OXT gene knockout mice (mice lacking the
gene for OXT) showed deﬁcits in other behaviors, such as,
decreased social investigation and increased aggression (Insel,
O’Brien, and Leckman., 1999). It is also found that OXT gene
knockout mice failed to develop social memory (Ferguson et al.,
2000). These behaviors and disorders are similar to the symptoms
of ADHD. Furthermore, it is suggested that ASD shares familial
transmission with ADHD, and that ADHD and ASD share a partially
overlapping diathesis (Musser et al., 2014). Based on these evi-
dences, we hypothesized that serum levels of OXT in patients with
ADHD are lowered than normal controls.
The objective of this study was to examine whether serum
levels of OXT in pediatric patients with ADHD, differ from those of
sex- and age-matched, neurotypical controls. In addition, we
investigated the relationship between serum OXT levels and the
clinical symptoms in ADHD patients.
2. Methods
2.1. Ethics statement
The ethics committee of Chiba University Graduate School of
Medicine approved the study protocol (IRB number 137), which
was performed in accordance with the Declaration of Helsinki II.
All subjects and their parents provided written informed consent
for study participation, after receiving a full explanation of the
study, as well as any potential risks and beneﬁts.
2.2. Study design and subjects
Thirty six pediatric patients with ADHD were recruited from
the outpatients of Chiba University Hospital. Twenty-two, age- and
sex- matched healthy, typically developing controls were recruited
via advertisements, from Chiba city residents. All patients were
diagnosed by child psychiatrist according to the DSM-IV criteria
for ADHD (American Psychiatric Association, 1994), and were
classiﬁed into three subtypes; inattentive subtype (n¼19), com-
bined (inattentive and hyperactive/impulsive) subtype (n¼16) and
hyperactive/impulsive subtype (n¼1). None of the patients ful-
ﬁlled any of ASD, and mood disorders (depressive disorders and
bipolar disorders) according to DSM-IV criteria (American
Psychiatric Association, 1994), while patients with other psychia-
tric comorbidities (learning disorders, tic disorders, oppositional
deﬁant disorders) were included. Neurotypical controls (n¼22)
underwent a comprehensive medical history assessment to elim-
inate those with neurological and other medical disorders. The
Mini International Neuropsychiatric Interview for Children and
Adolescents (MINI-KID) was also conducted to exclude current and
past, personal and familial histories of mental illnesses (Sheehan
et al., 2010). None of the typically developing controls fulﬁlled any
of these exclusion criteria.
Table 1
Demographics and clinical characteristics of ADHD subjects and neurotypical controls.
ADHD total
(n¼36)
ADHD drug
naïve (n¼23)
ADHD
medicated
(n¼13)
Neurotypical
controls (n¼22)
ADHD vs
controls
ADHD drug naïve vs ADHD
medicated vs controls
t p F p
Age (years) 9.8672.332 10.3072.476 9.0871.891 10.9172.635 1.668 0.106a 2.338 0.106b
Age range (years) 6–15 6–15 6–14 7–15 – – – –
Gender (male/female) 26/10 15/8 11/2 11/11 – 0.088c – 0.118c
Race (% Japanese) 100 100 100 100 – – – –
ADHD subtypes (combined/
inattentive/hyperactive–
impulsive)
19/16/1 11/11/1 8/5/0 – – – – –
ADHD-RS Total Score 25.31711.459 26.65710.641 22.92712.874 – – – – –
ADHD-RS Hyper/Impulsive Score 10.4777.069 10.8776.864 9.7777.650 – – – – –
ADHD-RS Inattentive Score 14.8375.868 15.7875.681 13.1576.039 – – – – –
WISC-III/IV Full IQ Score 88.6 715.272 88.70715.372 88.42715.756 – – – – –
Co-morbidity (number) 4 3 1 – – – – –
Learning disorder 1 1 0 – – – – –
Tic disorder 1 1 0 – – – – –
Oppositional deﬁant disorder 1 1 0 – – – – –
Learning disorder and oppositional
deﬁant disorder
1 0 1 – – – – –
Pharmacotherapy (number) 13 – 13 – – – – –
Methylphenidate 6 – 6 – – – – –
Atomoxetine 3 – 3 – – – – –
Aripiprazole 2 – 2 – – – – –
Methylphenidate and Atomoxetine 2 – 2 – – – – –
Drug naïve (number) 23 23 0 22 – – – –
Serum levels of oxytocin (pg/ml) 60.687737.143 49.295721.541 80.843749.842 99.876728.566 4.237 o
0.001nnna
14.068 o 0.001nnnd, (o0.001nnna,e,
0.048na,f, 0.072a,g)
Reported values are means7S.D. (standard deviation), percentages, ranges.
Abbreviations: ADHD: Attention Deﬁcit/Hyperactivity Disorder; ADHD-RS: Attention Deﬁcits/Hyperactivity Disorder-Rating Scale IV Japanese version; WISC-III/IV: the
Wechsler Intelligence Scale for Children-III/IV
n Statistically signiﬁcant at po0.05.
nnn Statistically signiﬁcant at po0.001.
a Student's t-test and Mann–Whitney U test and Bonferroni correction post hoc were employed for continuous variables between the two groups.
b One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test was used for comparisons among the ADHD medicated group, ADHD drug naïve
group and healthy normal controls.
c χ2 test.
d Kruskall–Wallis test,
e ADHD drug naïve vs neurotypical controls,
f ADHD drug naïve vs ADHD medicated,
g Neurotypical controls vs ADHD medicated.
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2.3. Measurement of clinical symptoms
All patients were assessed using the ADHD-Rating Scale IV
Japanese parents' version (ADHD-RS) (DuPaul et al., 2008). The
ADHD-RS is a reliable and easy-to-administer instrument both for
diagnosing ADHD in children and adolescents, and for assessing
treatment response. Containing 18 items, the scale is linked
directly to DSM-IV diagnostic criteria for ADHD (Tani et al.,
2010). The Wechsler Intelligence Scale for Children – Third Edition
(WISC-III) or Fourth Edition (WISC-IV), Japanese version was used
to assess the Full Intelligent Quotient (FIQ) of patients with ADHD
(David, 1998, 2010).
2.4. Measurement of OXT levels from serum
Serum samples from patients and typically developing control
subjects were collected between 10:00 and 15:00 h, and stored at
80 1C until assayed. Serum OXT levels were measured using the
OXT ELISA kit (Catalog no. ADI-900-153, ENZO Life Sciences, Farm-
ingdale, NY, USA). In order to eliminate the effect of potentially
interacting molecules, we performed a solid-phase extraction of
serum samples. Brieﬂy, an equal volume (250 μL) of 0.1% triﬂuor-
oacetic acid in water (TFA-H2O) was added to serum samples
(250 μL) and centrifuged at 17,000 g for 15 min, at 4 1C. The
supernatant was collected. C18 Sep-Pak columns (200 mg, Waters
Corporation Milford, Massachusetts USA) were equilibrated with
1 mL of acetonitrile, followed by four applications with 3 mL of 0.1%
TFA-H2O. The supernatant was applied to the C18 Sep-Pak column,
and washed four times with 3 mL of 0.1% TFA-H2O, and the ﬂow-
through fraction was discarded. Next, the sample was eluted slowly
by applying 3 mL of a solution comprising 60% acetonitrile and 40%
0.1% TFA-H2O, and the eluent collected in a plastic tube. The solvent
was evaporated using a centrifugal concentrator under vacuum at
4 1C, and the remaining sample was stored at 20 1C, before assay.
The samples were reconstituted in assay buffer provided with the
ELISA kit, and the assay was performed according to the manufac-
turer's protocol. Absorbance at 405 nmwas then measured using an
Emax automated microplate reader (Molecular Devices, Tokyo). All
assays were performed in duplicate.
2.5. Statistical analysis
Statistical analyses were performed using the software package
SPSS Version 21.0, for Macintosh (IBM Armonk, NY, USA). Chi-
squared test was used for categorical variables. Student's t-test and
Mann–Whitney U test were employed for continuous variables
between the two groups. Levene's test was used to determine
whether variables showed equal variance. One-way analysis of
variance (ANOVA) followed by Tukey's multiple comparison was
used for comparisons of age in the ADHD medicated and ADHD
naïve groups, and neurotypical controls. Kruskall–Wallis test was
used for comparisons of serum levels of OXT in the ADHD
medicated and ADHD naïve groups, and neurotypical controls.
Bonferroni correction was used for post hoc test. Pearson's and
Spearman's correlation coefﬁcients and forced entry multiple
regression analysis were employed to detect correlations between
serum OXT levels and clinical variables. Statistical signiﬁcance was
set at Po0.05 (two-tailed) with Power (1β)¼0.80. Wilcoxon–
Mann–Whitney test with 36 total ADHD samples and 22 neuro-
typical control samples, 23 ADHD naïve samples, 13 ADHD
medicated samples would have enabled us to detect the following
effect sizes: total ADHD vs neurotypical controls; d¼0.79 (med-
ium-to-large), ADHD naïve vs ADHD medicated; d¼1.03 (large),
ADHD naïve vs neurotypical controls; d¼0.86 (large), ADHD
medicated vs neurotypical controls; d¼1.03 (large).
3. Results
3.1. Sample characteristics
Demographic and clinical characteristics of ADHD subjects and
typically developing controls are shown in Table 1. Age and gender
status did not differ between total subjects with ADHD and
neurotypical controls. Age and gender also did not differ among
the neurotypical control group, the drug naïve ADHD and the drug
medicated ADHD groups. Twenty-three patients were drug-naïve,
while 13 patients were receiving drug therapy: methylphenidate
(n¼6, 18–36 mg/day), atomoxetine (n¼3, 30–50 mg/day), aripipra-
zole (n¼2, 3 mg/day) and a combination of atomoxetine and
methylphenidate (n¼2, 18–36 and 40–55 mg/day, respectively).
One subject was also diagnosed as having a learning disorder; one
subject was diagnosed with tic disorder; one subject was diagnosed
with oppositional deﬁant disorder and one with learning and
oppositional deﬁant disorders, according to the DSM-IV criteria.
3.2. Serum OXT levels
As seen in Table 1 and Fig. 1, serum levels of OXT in total
subjects with ADHD (the mean7S.D.: 60.687737.143 pg/ml)
were signiﬁcantly (t¼4.237, d.f.¼56, Po0.001) lower than neuro-
typical controls (the mean7S.D.: 99.876728.566 pg/ml). Krus-
kall–Wallis test detected signiﬁcant (Po0.001) differences in OXT
serum levels among the neurotypical control group, the drug naïve
ADHD and the drug medicated ADHD groups. Interestingly, serum
levels of OXT in the drug medicated ADHD group showed
signiﬁcantly (P¼0.048) higher than their drug naïve counterparts,
while there was no difference (P¼0.072) between the drug
medicated ADHD groups and neurotypical controls. Furthermore,
there was a signiﬁcant negative correlation between OXT serum
levels and ADHD-RS total scores (Spearman's correlation:
r¼0.343, P¼0.040), and ADHD-RS inattentive scores (Spear-
man's correlation: r¼0.352, P¼0.035), in all ADHD patients.
Meanwhile, there was no correlation between serum levels of OXT
Fig. 1. The serum levels of OXT in neurotypical controls and ADHD patients. The
serum levels of OXT in ADHD (n¼36) were signiﬁcantly (Po0.001, t¼4.273, d.
f.¼56) lower than those of neurotypical controls (n¼22). Kruskall–Wallis test,
detected signiﬁcant differences in OXT serum levels between the neurotypical
controls and the drug naïve ADHD and the drug medicated ADHD groups.
(Po0.001). Mann–Whitney U test and Bonferroni post hoc correction detected
signiﬁcant differences between the serum levels of OXT in the drug medicated ADHD
group and drug naïve ADHD group (P¼0.048), while no signiﬁcant differences
between the drug medicated ADHD groups and neurotypical controls (P¼0.072).
Abbreviations: ADHD, Attention Deﬁcit/Hyperactivity Disorder; OXT, Oxytocin.
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and ADHD-RS hyperactivity/impulsive scores (Spearman's correla-
tion: r¼0.204, P¼0.232) in the ADHD groups (Fig. 2). Regression
analysis revealed no association between the serum levels of OXT
in all ADHD patients and their IQ score (d.f.¼1, F¼2.184, P¼0.149).
4. Discussion
In this study, we found that serum OXT levels in total subje-
cts with ADHD were signiﬁcantly lower than those of age- and
sex- matched neurotypical controls. To the best of our knowledge,
this is the ﬁrst report demonstrating decreased serum levels of
OXT in ADHD patients. Interestingly, serum levels of OXT were
signiﬁcantly higher in medicated ADHD patients than in drug
naïve counterparts. Additionally, there were signiﬁcant negative
correlations between serum OXT levels and ADHD-RS total and
inattentive scores in all ADHD patients.
Accumulating evidence highlights the signiﬁcant role OXT plays in
the human limbic system, including the amygdala (Bale et al., 2001;
Landgraf and Neumann, 2004; Huber et al., 2005; Domes et al.,
2007). Experimental animal studies suggest that the social memory
effects of OXT are mediated by the amygdala (Ferguson et al., 2001,
2002), hinting at an important role for the amygdala in mediating the
socio-affective action of OXT. A recent meta-analysis showed that
alterations in limbic regions, such as the anterior cingulate cortex and
amygdala, are more pronounced in untreated ADHD populations, and
that these changes seemed to diminish over time from childhood to
adulthood in ADHD patients (Frodl and Skokauskas, 2012). This study
also found that treatment for ADHD patients appeared to confer a
beneﬁcial effect on brain structure (Frodl and Skokauskas, 2012). It is
highly likely that the pathophysiological effect of ADHD therapies
involve OXT regulation and the amygdala.
Lower levels of peripheral OXT have been reported in some
studies on ASD, depression and schizophrenia, although the
ﬁndings vary (Modahl et al., 1998; Green et al., 2001; Macdonald
and Feifel, 2012; Meyer-Lindenberg et al., 2011; Striepens et al.,
2011; Yamasue et al., 2012; Stavropoulos and Carver, 2013). In
contrast, a positive correlation was found between OXT levels and
symptom severity in patients with social anxiety disorder
(Striepens et al., 2011), indicating that excessive attention may
raise peripheral OXT levels. Interestingly, our study found a
negative correlation between OXT levels and inattentiveness in
ADHD patients. Therefore, peripheral OXT levels might be asso-
ciated with attention deﬁcit symptoms. It has also been suggested
that peripheral OXT levels may indicate a sensitivity to socially-
relevant information (Bartz et al., 2011). Previous study shows that
plasma OXT was negatively associated with daily living skills and
interpersonal relations (Vineland Adaptive Behavior Scale scores)
Fig. 2. Relationship between serum levels of OXT and ADHD-RS total scores, inattentive scores and hyperactivity-impulsive scores in ADHD. There were signiﬁcant negative
correlations between ADHD-RS total scores (Spearman's correlation: r¼ 0.343, P¼0.040) and ADHD-RS inattentive scores (Spearman's correlation: r¼0.352, P¼0.035)
with OXT serum levels in patients (n¼36) with ADHD. However, there was no correlation between serum levels of OXT and ADHD-RS hyperactivity/impulsive scores
(Spearman's correlation: r¼0.204, P¼0.232) in these patients. Abbreviations: ADHD, Attention Deﬁcit/Hyperactivity Disorder; ADHD-RS, Attention Deﬁcit/Hyperactivity
Disorder-Rating Scale IV Japanese version; OXT, oxytocin.
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in the ASD group (Modahl et al., 1998). Furthermore, plasma OXT-
extended formwas correlated positively with an Autistic Disorders
Checklist (ADC) item, regarding the presence of stereotypies and
negatively with an ADC item regarding abnormalities in comfort-
giving within the ASD group (Green et al., 2001). However, plasma
OXT levels of their reports including ASD and controls are very low
or the under the limitation (0–6 pg/ml), although serum levels of
OXT in our study are detectable (22–222 pg/ml). The reasons for
this discrepancy are currently unknown. One possibility of this
discrepancy may be the difference in the source of blood sample
(serum vs plasma). Another possibility is due to ethnic difference
(Caucasian vs Japanese). Nonetheless, further studies using larger
sample sizes will be needed to address these points.
Recently, it is shown that genetic variations of the OXT receptor gene
inﬂuenced social cognition, and that this association may be present in
other diagnostic groups that display impaired social communication
(Park et al., 2010). Furthermore, recent evidence shows that OXT
improves emotion recognition and social approach in people with
ASD (Guastella et al., 2009; Andari et al., 2010; Kosaka et al., 2012),
suggesting that it may have therapeutic implications for individuals
with ADHD and other diagnoses with social cognitive deﬁcits.
Recently, it has been reported that intranasal administration of OXT
(24IU) enabled ASD patients to make nonverbal information-based
judgments more frequently, with a shorter response time (Watanabe
et al., 2014). In addition, during the test period, OXT increased
diminished brain activity in the medial prefrontal cortex, typically
seen in ASD patients (Watanabe et al., 2014). Moreover, OXT enhanced
functional coordination in the area, and the magnitude of these neural
effects was predictive of the behavioral effects in ASD sufferers
(Watanabe et al., 2014). Therefore, it is likely that OXT treatment
may confer beneﬁcial effects on the sociocommunicational deﬁcits of
ADHD, in a similar manner to ASD, especially since previous studies
showed that reduced cortical thickness in the medial prefrontal cortex
is associated with a worse prognosis for ADHD (Shaw et al., 2006).
Although the development of OXT for therapeutic use is still in the
early stages, its ability to increase trust and enhance emotional
empathy suggests considerable potential in neuropsychiatry. This
could be either as an addition to other medications, or in combination
with psychotherapy for ADHD and other diagnoses with social
cognitive deﬁcits.
The main limitation of this study is its small sample size.
Furthermore, we did not compare the serum levels of OXT in ASD
patients, although ADHD and ASD are highly comorbid. Therefore,
further studies using larger sample sizes of ASD cohorts will be
needed to conﬁrm these results.
In conclusion, this study suggests that decreased levels of OXT may
play a role in the pathophysiology of patients with ADHD and its inherent
inattentiveness, although further research is needed in this area.
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